News & Updates

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA

ATTD-ASIA 2024, held recently in Singapore, was a huge success, with nearly 800 delegates from 49 countries gracing the event. ATTD-Asia 2024 chair, Professor Moshe Phillip, said the event brought together top diabetes experts to ensure patients can access the latest technologies and treatments for diabetes. MIMS Doctor reports highlights and snippets from the conference.

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

The post-pandemic burden of COVID-19 remains significant in adults. Four studies from IDWeek 2024 highlight the benefits of nirmatrelvir-ritonavir (NMV/r) for high-risk adults with SARS-CoV-2 immunity and link chronic conditions to COVID-19 hospitalization. Identifying high-risk patients and using NMV/r in outpatient settings can reduce severe outcomes.

Clinical considerations for patients at high risk for progression to severe COVID-19

COVID-19 has not gone away. New contagious variants continue to be a leading cause of death, with underlying conditions still influencing the risk of COVID-19 hospitalizations, said Dr Ali Hassoun, Clinical Professor of Medicine and infectious disease specialist at Crestwood Medical Center, Huntsville, Alabama, US, who spoke at a Pfizer-sponsored session during IDWeek 2024.

To Obesity and Beyond: The Effects of GLP-1 RA for Weight Managements on Cardiovascular Health

Debunking the myths about DPP-4 inhibitors

Navigating the evolving landscape of diabetes management requires precise knowledge. In this exploration into the world of DPP-4 inhibitors (DPP4is), we aim to debunk prevalent myths and provide nuanced insights.

Robust evidence for fenofibrate in patients with metabolic syndrome on statins

The latest ESC-EAPCI Consensus statement on Renal Denervation by Prof Felix Mahfoud

The latest ESC-EAPCI Consensus statement on Renal Denervation by Prof Felix Mahfoud

EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute heart failure

Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.